Vir Biotechnology, Inc. Uncategorized Contracts & Agreements
23 Contracts & Agreements
- Letter Agreement between the Company and Glaxo Wellcome UK Limited, dated February 21, 2024 (Filed With SEC on May 3, 2024)
- Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated January 12, 2022 (Filed With SEC on February 28, 2022)
- Amended and Restated Letter Agreement between the Company and the Bill & Melinda Gates Foundation, dated January 12, 2022 (Filed With SEC on February 28, 2022)
- Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated November 5, 2021 (Filed With SEC on February 28, 2022)
- Amendment No. 5 to Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated December 8, 2021 (Filed With SEC on February 28, 2022)
- Amendment No. 4 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated December 8, 2020 (Filed With SEC on February 25, 2021)
- Amendment No. 3 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated May 22, 2020 (Filed With SEC on February 25, 2021)
- Letter Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 23, 2020 (Filed With SEC on February 25, 2021)
- Promotion Letter Agreement between the Company and Steven Rice, dated July 30, 2020 (Filed With SEC on November 10, 2020)
- Amendment No. 3 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated May 29, 2020 (Filed With SEC on August 11, 2020)
- Letter of Intent between the Company and Wuxi Biologics (Hong Kong) Limited, dated June 15, 2020 (Filed With SEC on July 6, 2020)
- Binding Letter Agreement between the Company and Samsung Biologics Co., Ltd., dated April 9, 2020 (Filed With SEC on July 6, 2020)
- Amendment No. 2 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated October 28, 2019 (Filed With SEC on March 26, 2020)
- Amendment No. 1 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated April 22, 2019 (Filed With SEC on March 26, 2020)
- Amendment No. 2 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated February 24, 2020 (Filed With SEC on March 26, 2020)
- Amendment No. 1 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated April 18, 2019 (Filed With SEC on March 26, 2020)
- Amendment Agreement between the Registrant (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated January 29, 2018 (Filed With SEC on September 3, 2019)
- Grant Agreement between the Registrant and the Bill & Melinda Gates Foundation, dated March 16, 2018 (Filed With SEC on September 3, 2019)
- Grant Agreement between the Registrant and the Bill & Melinda Gates Foundation, dated January 26, 2018 (Filed With SEC on September 3, 2019)
- Letter Agreement between the Registrant and the Bill & Melinda Gates Foundation, dated December 23, 2016 (Filed With SEC on September 3, 2019)
- Letter Agreement between the Registrant and the stockholders of TomegaVax, Inc. set forth therein, dated September 12, 2016 (Filed With SEC on September 3, 2019)
- Letter Agreement between the Registrant and Alnylam Pharmaceuticals, Inc., dated November 13, 2018 (Filed With SEC on September 3, 2019)
- Form of Indemnity Agreement by and between the Registrant and its directors and executive officers (Filed With SEC on September 3, 2019)
